Use of continuous glucose monitoring when initiating glucagon‐like peptide ‐ 1 receptor agonist therapy in insulin‐treated diabetes
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15883 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Irl B Hirsch und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Washington School of Medicine, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Diabetes Mellitus, Type 1, Hypoglycemia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 83 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) medications have been shown to be effective in achieving optimal glucose control and reducing all‐cause death, cardiovascular death, nonfatal myocardial infarction, hospitalization for heart failure, and end‐stage kidney disease in individuals with type 1 (T1D) and type 2 diabetes (T2D). However, use of these medications has been associated with increased hypoglycaemia risk in patients treated with concomitant antihyperglycaemic medications. The risk is particularly high in patients with T1D due to their loss of glucagon counter‐regulatory response. This article reviews the effect of GLP‐1RA formulations on the development of hypoglycaemia in individuals with T1D and T2D treated with insulin therapy, discusses the benefits of continuous glucose monitoring with GLP‐1RA treatment, and presents strategies for safely initiating GLP‐1RA therapy in these individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Washington School of Medicine, Seattle, Washington, USA.
- CGParkin Communications, Inc, Henderson, Nevada, USA.
- University of California San Diego School of Medicine, La Jolla, California, USA.
- International Diabetes Centre, HealthPartners Institute, Minneapolis, Minnesota, USA.
ORCID-Profile: Christopher G Parkin, Richard M Bergenstal
Zitieren
APA
Hirsch, I. B., Parkin, C. G., Cavaiola, T. S., & Bergenstal, R. M. (2024). Use of continuous glucose monitoring when initiating glucagon‐like peptide ‐ 1 receptor agonist therapy in insulin‐treated diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15883
Vancouver
Hirsch IB, Parkin CG, Cavaiola TS, Bergenstal RM. Use of continuous glucose monitoring when initiating glucagon‐like peptide ‐ 1 receptor agonist therapy in insulin‐treated diabetes. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15883
BibTeX
@article{Hirsch2024,
author = {Hirsch, Irl B and Parkin, Christopher G and Cavaiola, Tricia Santos and Bergenstal, Richard M},
title = {Use of continuous glucose monitoring when initiating glucagon‐like peptide ‐ 1 receptor agonist therapy in insulin‐treated diabetes},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15883}
}
EUVIMED